Skip to contentC
China Pharma Holdings, Inc.
C
CPHIChina Pharma Holdings, Inc. Q2 2022 · 10-Q
Revenue$1.61M$1.61M−33.2% vs Q2 2021 Net Income-$888.39K-$888.39KN/M vs Q2 2021 EPS Diluted-$0.18-$0.18N/M vs Q2 2021 The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
China Pharma Holdings, Inc. · CIK 1106644 · Engraved from SEC EDGAR
Operating Cash Flowderived-$333,823N/M Free Cash Flowderived-$509,114— Margins · derivedGross margin-14.2%−17.2 pt vs Q2 2021
Operating margin-48.3%−17.2 pt vs Q2 2021
Net margin-55.1%−20.9 pt vs Q2 2021
ended Jun 30, 2022 · filed Aug 11, 2022 · 42 d after period end